Skip to main
STAA
STAA logo

STAAR Surgical (STAA) Stock Forecast & Price Target

STAAR Surgical (STAA) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 54%
Buy 0%
Hold 38%
Sell 8%
Strong Sell 0%

Bulls say

Staar Surgical Co. is projected to achieve a revenue growth of 7% year-over-year in 2026, indicating a strong trajectory based on a normalized sales base of $146 million in 2025, supported by market growth and increasing market share in Implantable Collamer lenses (ICL). The company is expected to benefit from a successful domestic launch of the EVO product and enhanced adoption internationally, which can drive above-market volume growth while also improving the cost structure. Additionally, management has highlighted opportunities for margin improvement and long-term growth positioning, reinforcing a positive outlook on Staar Surgical's financial performance.

Bears say

Staar Surgical Co. faces a negative outlook primarily due to projected flat to declining revenue growth, heavily influenced by high inventory levels attributed to its new distributor in China, leading to significant sales hits in the upcoming quarters. The company’s earnings have also been adversely affected by macroeconomic conditions and risks associated with patients' ability to afford out-of-pocket expenses for their products, as well as potential losses in market share to more cost-effective alternatives. Additionally, ongoing geopolitical uncertainties concerning China's market exposure further compound the challenges impacting Staar Surgical's financial performance.

STAAR Surgical (STAA) has been analyzed by 13 analysts, with a consensus rating of Buy. 54% of analysts recommend a Strong Buy, 0% recommend Buy, 38% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of STAAR Surgical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About STAAR Surgical (STAA) Forecast

Analysts have given STAAR Surgical (STAA) a Buy based on their latest research and market trends.

According to 13 analysts, STAAR Surgical (STAA) has a Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $53.23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $53.23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

STAAR Surgical (STAA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.